MediView, LLC is a medical device company based in Cleveland, Ohio, founded in 2017. It specializes in augmented reality surgical navigation systems aimed at enhancing the surgical process for healthcare providers. The company's flagship product utilizes extended reality technology to improve the accuracy and efficacy of cancer therapies, specifically in the ablation and biopsy of cancerous tumors. MediView's innovative approach includes real-time, fused-holographic visualization, allowing surgeons to navigate procedures with 3D augmented reality. This technology supports telehealth initiatives and enables remote collaboration, allowing for a more effective examination of patients compared to traditional 2D displays.
Lucem Health develops a remote diagnostics platform designed to connect remote patient telemetry and biosensing devices with AI algorithms. Lucem's platform focuses on data ingest, orchestration, and connectivity, enabling clinicians to provide more effective continuous care and empower consumers to have better control of their health and well-being.
Karkinos Healthcare is a technology-driven platform that focuses on oncology, aiming to provide accessible cancer care and early diagnosis of common cancers. The company develops comprehensive healthcare solutions that bring cancer services closer to patients, ensuring that access and affordability do not hinder individuals from receiving necessary care. By emphasizing early detection and diagnosis, Karkinos Healthcare strives to improve patient outcomes and make cancer care more inclusive for everyone.
Medically Home Group, Inc., based in Boston, Massachusetts, offers a virtual hospital program designed to deliver in-home medical care services. Founded in 2016, the company focuses on providing patient-centered care for individuals with serious or complex illnesses, including conditions such as heart failure, pneumonia, urinary tract infections, cellulitis, and respiratory issues. Medically Home's innovative model enables the safe transition of medical care from traditional hospital settings to patients' homes, allowing for centralized, on-demand management of acute medical needs. This approach connects patients with caregivers while facilitating monitoring and communication, ensuring that patients and their families receive comprehensive support in a familiar environment.
SimBioSys, Inc. is developing a Computational Microscope that integrates state-of-the-art simulation techniques with a diverse set of experimental datasets to provide new insight into the behavior of cancers. The technology allows researchers to peer into the cancer microenvironment to identify the behavior of tumors: the cell phenotypes, how they interact with surrounding tissues, and how they prime their neighbors for invasion, all from the comfort of their computer desk.
JOGO Health specializes in digital therapeutics aimed at treating neuromuscular conditions and chronic pain. The company utilizes a combination of wearable sensors and a patented mobile application that employs artificial intelligence, machine learning, and virtual reality to deliver tailored treatment protocols and interactive games. These solutions focus on muscle relaxation, movement coordination, and neuromuscular re-education, all rooted in the principles of neuroplasticity. JOGO therapy is administered through a service model that can occur in medical offices, during home visits, or via telemedicine, facilitated by certified therapists. The company's approach received FDA 510(k) exemption in March 2020, and its services are reimbursed by Medicare and commercial payers for neuro-muscular re-education, thereby enhancing patient adherence to rehabilitation and improving overall health outcomes.
Senda Biosciences is pioneering the field of Intersystems Biology to create novel treatments for human disease. Intersystems Biology focuses on how molecular connections between botanical, bacterial, and human cells—coevolved over millennia—define health and disease. Senda's Intersytems Biology discovery platform, built using new techniques in machine learning and computational biology, has been able to generate novel, actionable insights into the trillions of interspecies molecular connections in the human body, and harnesses the power of this "pharmacy within us" with novel pharmacological approaches. The power of the Senda platform is illustrated by six preclinical programs in oncology, neurology, chronic disease, and metabolic disease.
Helix is a prominent population genomics company that operates at the intersection of clinical care, research, and data analytics. The company provides an end-to-end platform designed to facilitate genomic research and the incorporation of genomic data into healthcare practices. Helix operates one of the largest CLIA/CAP-certified next-generation sequencing laboratories and utilizes its proprietary Exome+™ assay to support various aspects of population genomics. These include recruitment and engagement, clinically actionable disease screening, and the return of results. Additionally, Helix engages in large-scale genetic analysis and viral surveillance, delivering actionable genetic insights that aid health systems, life sciences companies, payers, and government entities in enhancing patient care and informing public health decisions.
Medically Home Group, Inc., based in Boston, Massachusetts, offers a virtual hospital program designed to deliver in-home medical care services. Founded in 2016, the company focuses on providing patient-centered care for individuals with serious or complex illnesses, including conditions such as heart failure, pneumonia, urinary tract infections, cellulitis, and respiratory issues. Medically Home's innovative model enables the safe transition of medical care from traditional hospital settings to patients' homes, allowing for centralized, on-demand management of acute medical needs. This approach connects patients with caregivers while facilitating monitoring and communication, ensuring that patients and their families receive comprehensive support in a familiar environment.
Glooko is a comprehensive diabetes management platform designed to enhance health outcomes for individuals with diabetes and their healthcare teams. It connects with various diabetes devices and fitness trackers to gather essential data, including glucose levels, food intake, insulin usage, medications, blood pressure, diet, and weight. The platform is utilized in over 7,000 clinical locations and serves more than 1.5 million people with diabetes across 23 countries and in 15 languages. Glooko aims to facilitate remote patient monitoring by providing healthcare providers with valuable insights and analytics, ultimately supporting interventions that improve patient care and promote healthier behaviors.
Diagnostic Robotic develops a signal-agnostic artificial intelligence system for healthcare insurers, providers, and patients. It allows to build powerful predictive analytics models that will solve a world-wide challenge, strained health budgets, and workforces.
Diagnostic Robotic was founded on 2017 and is headquartered in Tel Aviv, Israel.
Progentec Diagnostics, Inc. specializes in developing diagnostic tests aimed at managing autoimmune diseases, particularly systemic lupus erythematosus (SLE). The company offers the aiSLE DX platform, which includes a flare prediction score that enables proactive measurement of disease activity and an early diagnostic test for lupus. Founded in 2015 and headquartered in Oklahoma City, Oklahoma, Progentec collaborates with various research institutions and healthcare professionals to integrate advanced diagnostic interventions with digital technologies. This collaboration aims to enhance disease management, reduce healthcare costs, and improve patient outcomes through early detection and better care delivery.
Elysium Health, Inc. develops and produces health supplements focused on cellular health, long-term brain health, and biological age testing. Founded in 2014 and based in New York, the company sells its products online, aiming to enhance health and longevity through scientifically backed solutions. Elysium collaborates with scientists, clinicians, and health professionals globally to identify and formulate natural compounds. Its flagship product features a proprietary combination of ingredients designed to support overall well-being at the cellular level, addressing contemporary health challenges with a foundation in scientific research.
Hui-Gene Therapeutics Co., Ltd. is a biotechnology company based in Shanghai, China, founded in 2018. The company specializes in the research and development of treatments for single-gene disorders and has also initiated projects targeting neurodegenerative diseases and vision disorders. By concentrating on these areas, Hui-Gene aims to advance therapeutic options for conditions often tied to genetic anomalies.
NewCompliance Group B.V. develops and delivers dashboards that provide insights and improves the safety and efficiency in hospitals during the entire surgical process. It offers Operating Room Cockpit system that integrates and draws data from EMR, building, and other operating room (OR) equipment. The company’s OR Cockpit tracks, validates, and interprets data and display essential information needed by clinical staff during procedures. It also provides OR Financial that OR managers and hospital executives detailed and complete insight into the cost of individual surgeries by bringing together existing data; and OR Analytics platform that draws data from the EMR, facilities, and other major OR equipment to allow the user to design any type of combined and visual analysis in real-time. The company serves customers in Europe and the United States. The company was founded in 2006 and is based in The Hague, the Netherlands with additional offices in Nijmegen, the Netherlands; San Rafael, California; and Houston, Texas.
Eko harnesses the power of smartphones and cloud data for monitoring patients with cardiovascular diseases. It has built a platform of non-invasive cardiovascular monitoring devices, clinical software, and point-of-care decision support algorithms to improve the delivery of cardiovascular care. In 2015, Eko launched the Eko Core Digital Stethoscope, the first FDA-cleared digital stethoscope on the market to wirelessly stream heart and lung sound to HIPAA-compliant software. For the first time in history, patient sounds can be integrated with electronic health records (EHRs) for more seamless referrals, documentation, and monitoring. Eko was established in 2013 and is based in Berkeley, California.
Safely Health operates an online platform designed to promote safe sexual practices by enabling users to import their test results and verify their STD and COVID-19 status. Founded in 2015 and based in Los Angeles, the company aims to create a trusted, private, and secure environment for individuals seeking to share their health information with potential partners. Safely Health is not just an app but a comprehensive healthcare initiative that collaborates with leading healthcare organizations, including Quest and Labcorp, as well as public health entities like the CDC. By partnering with nonprofit organizations, influencers, and social media platforms, Safely Health seeks to empower users to take control of their sexual health and reduce the spread of STDs, ultimately fostering a safer and more enjoyable dating experience.
Pendulum Therapeutics Inc., a microbiome company, produces microbiome-targeted medical probiotics. It offers Pendulum Glucose Control, a medical probiotic for the dietary management of type 2 diabetes. The company also develops prebiotics to help feed the probiotic strains. It sells its products online. Pendulum Therapeutics Inc. was formerly known as Whole Biome Inc. and changed its name to Pendulum Therapeutics Inc. in July 2019. The company was incorporated in 2012 and is based in San Francisco, California.
Rheostat’s mission is to invent novel treatments for neurodegenerative disease through modulation of mitophagy and autophagy. They believe that the degradation of toxic cellular components, whether they are damaged organelles or aggregated proteins, is a fundamental node of biology. Mutations that impair these clearance pathways cause multiple neurodegenerative diseases, many of which are associated with cognitive impairment. They aim to leverage our understanding of these critical pathways to discover and develop novel small molecules that will restore cellular balance and treat neurodegenerative and rare diseases.
Marigold Health operates a social network community platform designed to provide text-based group therapies for individuals facing mental health and substance use challenges. The platform facilitates anonymous chat support groups, allowing patients to connect with peers and receive assistance from coaches who have personal recovery experience. This approach not only fosters a stigma-free environment for recovery but also enhances patient engagement in community-based treatment. By partnering with treatment providers and managed care organizations within the Medicaid market, Marigold Health effectively augments traditional care models, enabling care teams to increase their capacity while delivering personalized support to patients.
Ambient Clinical Analytics is the creator of a software platform designed for data assimilation, communication and analytics. It is based on decision support tools initially deployed in the intensive care unit (ICU) or emergency department of hospitals. Our software consists of algorithms that mine data from electronic medical records (EMR). It then presents that data to the physicians and nurses so they may facilitate real-time clinical decision making and care delivery. These products are positioned as add on applications that are designed to easily integrate with the current major EMR providers.
Geneticure Inc. is a pharmacogenetic testing company focused on developing personalized medicine solutions for patients with hypertension. Founded in 2012 and based in Eden Prairie, Minnesota, the company offers a non-invasive genetic test that analyzes DNA from a cheek swab to identify genetic variants related to the renal, vascular, and cardiac systems. This information helps clinicians determine the most effective treatment options tailored to individual patients based on their unique genetic profiles. Geneticure's testing process includes DNA extraction, genotyping, and the provision of genetic results directly to healthcare providers, accompanied by a decision tree that prioritizes functional genes. This personalized approach aims to optimize blood pressure therapy and improve patient outcomes. Additionally, Geneticure is working on two more pharmacogenomic panels to expand its offerings in personalized medicine.
Eko harnesses the power of smartphones and cloud data for monitoring patients with cardiovascular diseases. It has built a platform of non-invasive cardiovascular monitoring devices, clinical software, and point-of-care decision support algorithms to improve the delivery of cardiovascular care. In 2015, Eko launched the Eko Core Digital Stethoscope, the first FDA-cleared digital stethoscope on the market to wirelessly stream heart and lung sound to HIPAA-compliant software. For the first time in history, patient sounds can be integrated with electronic health records (EHRs) for more seamless referrals, documentation, and monitoring. Eko was established in 2013 and is based in Berkeley, California.
Helixis
Venture Round in 2018
Helixis, Inc. is a company that develops low-cost molecular diagnostic products.
Helix is a prominent population genomics company that operates at the intersection of clinical care, research, and data analytics. The company provides an end-to-end platform designed to facilitate genomic research and the incorporation of genomic data into healthcare practices. Helix operates one of the largest CLIA/CAP-certified next-generation sequencing laboratories and utilizes its proprietary Exome+™ assay to support various aspects of population genomics. These include recruitment and engagement, clinically actionable disease screening, and the return of results. Additionally, Helix engages in large-scale genetic analysis and viral surveillance, delivering actionable genetic insights that aid health systems, life sciences companies, payers, and government entities in enhancing patient care and informing public health decisions.
Progentec Diagnostics, Inc. specializes in developing diagnostic tests aimed at managing autoimmune diseases, particularly systemic lupus erythematosus (SLE). The company offers the aiSLE DX platform, which includes a flare prediction score that enables proactive measurement of disease activity and an early diagnostic test for lupus. Founded in 2015 and headquartered in Oklahoma City, Oklahoma, Progentec collaborates with various research institutions and healthcare professionals to integrate advanced diagnostic interventions with digital technologies. This collaboration aims to enhance disease management, reduce healthcare costs, and improve patient outcomes through early detection and better care delivery.
Glooko is a comprehensive diabetes management platform designed to enhance health outcomes for individuals with diabetes and their healthcare teams. It connects with various diabetes devices and fitness trackers to gather essential data, including glucose levels, food intake, insulin usage, medications, blood pressure, diet, and weight. The platform is utilized in over 7,000 clinical locations and serves more than 1.5 million people with diabetes across 23 countries and in 15 languages. Glooko aims to facilitate remote patient monitoring by providing healthcare providers with valuable insights and analytics, ultimately supporting interventions that improve patient care and promote healthier behaviors.
DayTwo Ltd. is a precision medicine company based in Tel Aviv-Yafo, Israel, that focuses on using gut microbiome analysis to provide personalized health solutions for metabolic diseases such as diabetes, prediabetes, and obesity. Founded in 2015, the company utilizes gut microbiome sequencing to create tailored Food Prescriptions™ that help individuals manage their blood sugar levels, improve energy, and achieve weight loss. Their digital platform offers actionable dietary recommendations based on individual biometrics and lifestyle factors, ensuring that patients receive insights that are practical and easy to follow. DayTwo also employs a telehealth service, where Certified Diabetes Care and Education Specialists and Registered Dietitians support patients through a smartphone application, allowing for progress tracking and communication. The effectiveness of DayTwo's approach is measured using clinical outcomes such as A1C levels and Time In Range, with the potential for full fee reimbursement for those who adhere to the protocol.
AliveCor, Inc. is a technology company that develops digital medical-grade electrocardiograms, enabling users to monitor their heart health through mobile devices. Its flagship product, KardiaMobile, provides instant detection of common heart arrhythmias and allows users to track blood pressure and weight, as well as store recorded EKGs. The company also offers KardiaMobile 6L, a six-lead EKG device that allows patients to share detailed readings with their healthcare providers. Additionally, AliveCor has introduced KardiaCare, a digital health subscription service that facilitates the management of heart health at home. Founded in 2010 and headquartered in Mountain View, California, AliveCor is recognized for its pioneering efforts in using machine learning techniques to enhance cardiac care and improve early detection of conditions such as atrial fibrillation.
Second Genome’s mission is to transform lives with medicines developed through innovative microbiome science. Second Genome has built a novel platform for microbiome drug discovery. Second Genome has completed more than 400 microbiome studies, analyzing more than 75,000 samples, for internal R&D, as well as for external partners across government, academia, pharmaceutical, nutrition and industrial companies. The team leverages its microbiome analysis platform with its partners’ specific expertise to generate insightful findings that can accelerate research programs by elucidating the role of the microbiome in human health conditions, agriculture, animal health and other industries. The company has established a pipeline of therapeutic products for the treatment of inflammation and metabolic diseases.
Cardero Therapeutics is a start-up pharmaceutical company that is developing a novel class of therapeutics that induces the formation of new mitochondria (mitochondrial biogenesis) and enhances mitochondrial function in response to metabolic demand. Chronic depletion of mitochondria, the principal source of cellular ATP, has been directly linked to the progression of heart failure, sarcopenia, and neurodegeneration. Cardero Therapeutics is collaborating with numerous academic medical centers to advance novel drug candidates structurally based on a newly discovered human hormone that appears to fundamentally regulate mitochondrial density and function in all tissues. Cardero Therapeutics believes that enhancing myocyte bioenergetics will comprise an innovative therapeutic approach complementary to currently available cardiovascular drugs. The company’s clinical development focus is the lethal cardiomyopathy associated with orphan diseases characterized by loss of mitochondria in muscle and heart, resulting in heart failure that is poorly responsive to current medical interventions. Initial clinical trials are directed toward Duchenne muscular dystrophy and Friedreich’s ataxia.
Helix is a prominent population genomics company that operates at the intersection of clinical care, research, and data analytics. The company provides an end-to-end platform designed to facilitate genomic research and the incorporation of genomic data into healthcare practices. Helix operates one of the largest CLIA/CAP-certified next-generation sequencing laboratories and utilizes its proprietary Exome+™ assay to support various aspects of population genomics. These include recruitment and engagement, clinically actionable disease screening, and the return of results. Additionally, Helix engages in large-scale genetic analysis and viral surveillance, delivering actionable genetic insights that aid health systems, life sciences companies, payers, and government entities in enhancing patient care and informing public health decisions.
Lifecode, Inc. is a molecular diagnostics company specializing in next-generation sequencing (NGS) technology, particularly in the field of oncology. Based in Foster City, California, the company develops a range of NGS-based cancer assays, including its flagship product, the Lifecode Pan Cancer Somatic Panel, designed for use in metastatic and rare cancers, as well as for patients who have exhausted standard treatment options or are exploring clinical trials. Lifecode aims to facilitate informed treatment decisions by providing clinical information to healthcare providers. To address the complexities of genomic data interpretation, Lifecode has assembled a skilled team with expertise in various scientific disciplines, including data science and molecular biology. The company is supported by funding from prominent investors, and it operates with a dual focus on software development and clinical laboratory services. Lifecode’s innovative approach is positioned to enhance personalized cancer care through accessible and interpretable genomic insights.
Stride Health, Inc. operates a health benefits platform tailored for independent workers and part-time employees in the United States. The platform enables users to select and enroll in various affordable health coverage options, including dental, vision, and prescription insurance plans. Stride Health simplifies the process of finding suitable health insurance by providing personalized recommendations and tax deduction support, thereby helping customers maximize their take-home pay. The company, originally known as Covered, Inc., rebranded to Stride Health in March 2013 and has since been based in San Francisco, California. Through its services, Stride Health aims to make healthcare accessible and manageable for its users.
Assurex Health is a personalized medicine company dedicated to helping clinicians determine the right medication for individual patients with medical conditions. Assurex Health’s proprietary Genesight® technology is based on pharmacogenomics – the study of the genetic factors that influence an individual’s response to drug treatments – as well as evidence-based medicine and clinical pharmacology.
Ambra Health is a medical data and image management software-as-a-service company that provides a cloud-based platform for healthcare providers. The platform is designed to enhance imaging innovation and improve collaborative care workflows by offering secure and easy access to medical images. It serves a diverse clientele, including major health systems and radiology practices, enabling them to streamline their operations and enhance patient care. Ambra Health's solutions focus on agility, interoperability, and user-friendly design, allowing organizations to adopt and integrate the technology effectively while improving business outcomes. The company aims to meet the evolving needs of the healthcare industry by delivering innovative medical image management solutions.
Seres Health, now known as Seres Therapeutics, Inc., is a clinical-stage therapeutics company focused on the development of microbiome-based drugs aimed at treating various diseases associated with dysbiosis. The company specializes in Ecobiotic therapeutics designed to restore health by repairing the microbiome's function. Its lead product candidate, SER-109, is currently in Phase III clinical trials to prevent the recurrence of Clostridium difficile infection (CDI). Additionally, Seres is advancing several other candidates, including SER-287, which is in a Phase IIb study for ulcerative colitis, and SER-401, currently in Phase Ib trials for use in combination with checkpoint inhibitors in metastatic melanoma patients. Other candidates under development include SER-262 for initial CDI recurrence and SER-155 for modulating the microbiome in patients post-stem cell transplants. The company collaborates with organizations like Nestec Ltd. and Memorial Sloan Kettering Cancer Center, and was founded in 2010 in Cambridge, Massachusetts.
Better is a personal health assistant service founded in 2013 and based in Palo Alto, California. The company offers free access to symptom advice and a comprehensive health database, assisting users in collecting their health records from various medical providers. Better also provides round-the-clock support from healthcare professionals who help navigate insurance claims and schedule appointments. Developed in collaboration with Mayo Clinic and Social+Capital Partnership, the service combines free tools with premium access to a dedicated team of personal health assistants, enabling users to focus more on their health and less on the logistical aspects of healthcare management.
Pendulum Therapeutics Inc., a microbiome company, produces microbiome-targeted medical probiotics. It offers Pendulum Glucose Control, a medical probiotic for the dietary management of type 2 diabetes. The company also develops prebiotics to help feed the probiotic strains. It sells its products online. Pendulum Therapeutics Inc. was formerly known as Whole Biome Inc. and changed its name to Pendulum Therapeutics Inc. in July 2019. The company was incorporated in 2012 and is based in San Francisco, California.
Ambient Clinical Analytics is the creator of a software platform designed for data assimilation, communication and analytics. It is based on decision support tools initially deployed in the intensive care unit (ICU) or emergency department of hospitals. Our software consists of algorithms that mine data from electronic medical records (EMR). It then presents that data to the physicians and nurses so they may facilitate real-time clinical decision making and care delivery. These products are positioned as add on applications that are designed to easily integrate with the current major EMR providers.
Sanguine Biosciences, Inc. provides customizable specimen collection services across the United States, maintaining a biorepository of frozen samples from donors with various disease conditions. The company specializes in same-day collection and shipment of time-sensitive blood samples, ensuring that patient samples meet specific study requirements, including demographics and medical history. Sanguine supports clinical and pharmacogenomic studies by offering comprehensive biomaterials storage, sample collection with preferred anticoagulants, and the ability to aliquot samples into suitable volumes. The company collaborates with numerous U.S.-based clinics and hospitals for longitudinal studies and also offers products online. Founded in 2010 and located in Sherman Oaks, California, Sanguine utilizes innovative technology solutions to facilitate clinical trials, including participant recruitment and at-home data collection, thereby aiding clinicians in prescribing appropriate treatments.
Bluesight is a software tool developed by Kit Check, Inc. that focuses on substance tracking and drug diversion detection within hospital pharmacies. This platform is part of a broader suite of cloud-based solutions designed to enhance the efficiency of pharmacy operations, including medication tracking and kit automation. Kit Check, Inc. utilizes Internet of Things (IoT) technology to significantly reduce kit replenishment time while increasing accuracy and minimizing errors. The company serves hospitals and pharmacies throughout the United States and Canada, tracking a substantial volume of medication, which contributes to improved supply chain management and operational safety. Founded in 2011 and based in Washington, D.C., Kit Check continues to innovate in the healthcare technology sector.
The Kang San Global Medical Technology (Beijing) Co., Ltd. is a hi-tech enterprise of one for the country at all levels of the hospital to provide advanced specialist inspection services, and the establishment of the National Laboratory of Kang Sheng Global Medical Special Inspection Center. Of the center's national service network belongs wholly owned ...
Kardia Health Systems is a healthcare information technology firm offering the delivery of specialty medicine, starting with cardiology. Using Internet technology and a Software-as-a-Service (SaaS) business model, Kardia makes this technology accessible to practices of varying sizes. Kardia Health Systems, Inc. was incorporated in 2006 and is based in Golden Valley, Minnesota.
Kardia Health Systems is a healthcare information technology firm offering the delivery of specialty medicine, starting with cardiology. Using Internet technology and a Software-as-a-Service (SaaS) business model, Kardia makes this technology accessible to practices of varying sizes. Kardia Health Systems, Inc. was incorporated in 2006 and is based in Golden Valley, Minnesota.
Naviscan, Inc. is the leader in organ-specific molecular imaging. The company designs, manufactures, and distributes a high-resolution PET scanner which provides unprecedented visualization of small body parts. While Naviscan’s PET scanner can image virtually any body part that can fit into the gantry, it is most often utilized as an adjunct to conventional imaging technologies by clinicians who stage and manage breast cancer. Surgeons, radiologists, nuclear physicians, and oncologists in hospitals and breast clinics use our compact, mobile and easy-to-use PET scanner to precisely characterize breast cancer, enhance surgical planning, monitor patient response to therapy, and evaluate suspected recurrence.
Naviscan, Inc. is the leader in organ-specific molecular imaging. The company designs, manufactures, and distributes a high-resolution PET scanner which provides unprecedented visualization of small body parts. While Naviscan’s PET scanner can image virtually any body part that can fit into the gantry, it is most often utilized as an adjunct to conventional imaging technologies by clinicians who stage and manage breast cancer. Surgeons, radiologists, nuclear physicians, and oncologists in hospitals and breast clinics use our compact, mobile and easy-to-use PET scanner to precisely characterize breast cancer, enhance surgical planning, monitor patient response to therapy, and evaluate suspected recurrence.